Coverage from the ASCO20 Virtual Scientific Program
Focus on Lung Cancer
New! Chemo/immunotherapy Combo Promising for Treatment of Mesothelioma
Inoperable malignant pleural mesothelioma is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos. At the annual meeting of the ASCO 2020 Annual Meeting, held virtually May 29-31, a researcher from the Johns Hopkins Kimmel Cancer Center presented findings from a multicenter study that evaluated the efficacy of an immunotherapy/ chemotherapy combination for the disease (Abstract 9003).
Pembrolizumab + Chemo Continues to Improve Efficacy in Metastatic Nonsquamous NSCLC
With longer follow-up, pembrolizumab plus chemotherapy continued to improve efficacy outcomes in previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC) over placebo and chemotherapy, with a manageable toxicity profile, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 9582).
Immunotherapy Combo Plus Chemo Improves Survival in First-Line NSCLC
Findings from the phase III CheckMate-9LA trial demonstrated that nivolumab plus ipilimumab, given concomitantly with 2 cycles of chemotherapy, had a statistically significant and clinically meaningful survival benefit as a first-line treatment of metastatic non-small cell lung cancer (NSCLC).
First-Line Tiragolumab + Atezolizumab Improves Survival Among NSCLC Patients
Findings suggest that the anti-TIGIT antibody tiragolumab, when combined with atezolizumab, had a clinically meaningful improvement in overall response rate (ORR) and progression-free survival (PFS) compared to placebo plus atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC).
Pembrolizumab Plus Chemo Improves Survival in Extensive-Stage Small-Cell Lung Cancer
First-line pembrolizumab plus etoposide significantly improved progression-free survival (PFS) and prolonged overall survival (OS) among patients with extensive-stage small cell lung cancer (ES-SCLC) when compared to placebo plus etoposide, according to data presented during an oral presentation at the ASCO 2020 Annual Meeting (Abstract 9001).
Adjuvant Osimertinib Delays Recurrence in Localized NSCLC
Data from a phase III study demonstrated that treatment with osimertinib following surgery for localized non-small cell lung cancer (NSCLC) with an EGFR mutation significantly improved disease-free survival (DFS). The findings were presented at the ASCO 2020 Annual Meeting (Abstract LBA5).